Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.

PLoS One · 2015 · PMC4514835 · PMID 26208030

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Between-group statistical differences were assessed using unpaired t -tests, with p < 0.05 used to define a significant difference and p < 0.0001 used to define a highly significant difference.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.